Suppr超能文献

埃博拉病毒糖蛋白的感染性增强抗体。

Infectivity-enhancing antibodies to Ebola virus glycoprotein.

作者信息

Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y

机构信息

Laboratory of Microbiology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.

出版信息

J Virol. 2001 Mar;75(5):2324-30. doi: 10.1128/JVI.75.5.2324-2330.2001.

Abstract

Ebola virus causes severe hemorrhagic fever in primates, resulting in mortality rates of up to 100%, yet there are no satisfactory biologic explanations for this extreme virulence. Here we show that antisera produced by DNA immunization with a plasmid encoding the surface glycoprotein (GP) of the Zaire strain of Ebola virus enhances the infectivity of vesicular stomatitis virus pseudotyped with the GP. Substantially weaker enhancement was observed with antiserum to the GP of the Reston strain, which is much less pathogenic in humans than the Ebola Zaire and Sudan viruses. The enhancing activity was abolished by heat but was increased in the presence of complement system inhibitors, suggesting that heat-labile factors other than the complement system are required for this effect. We also generated an anti-Zaire GP monoclonal antibody that enhanced viral infectivity and another that neutralized it, indicating the presence of distinct epitopes for these properties. Our findings suggest that antibody-dependent enhancement of infectivity may account for the extreme virulence of the virus. They also raise issues about the development of Ebola virus vaccines and the use of passive prophylaxis or therapy with Ebola virus GP antibodies.

摘要

埃博拉病毒可在灵长类动物中引发严重出血热,致死率高达100%,然而对于这种极高的毒力,尚无令人满意的生物学解释。在此我们表明,用编码埃博拉病毒扎伊尔株表面糖蛋白(GP)的质粒进行DNA免疫产生的抗血清,增强了用该GP假型化的水疱性口炎病毒的感染性。用针对莱斯顿株GP的抗血清观察到的增强作用要弱得多,莱斯顿株在人类中的致病性远低于埃博拉扎伊尔病毒和苏丹病毒。加热可消除这种增强活性,但在存在补体系统抑制剂时增强活性增加,这表明除补体系统外的热不稳定因子是产生这种效应所必需的。我们还制备了一种增强病毒感染性的抗扎伊尔GP单克隆抗体和另一种中和该抗体的单克隆抗体,这表明存在具有这些特性的不同表位。我们的研究结果表明,抗体依赖性感染性增强可能是该病毒极高毒力的原因。它们还引发了关于埃博拉病毒疫苗开发以及使用埃博拉病毒GP抗体进行被动预防或治疗的问题。

相似文献

1
Infectivity-enhancing antibodies to Ebola virus glycoprotein.
J Virol. 2001 Mar;75(5):2324-30. doi: 10.1128/JVI.75.5.2324-2330.2001.
2
Epitopes required for antibody-dependent enhancement of Ebola virus infection.
J Infect Dis. 2007 Nov 15;196 Suppl 2:S347-56. doi: 10.1086/520581.
6
Protective efficacy of neutralizing antibodies against Ebola virus infection.
Vaccine. 2007 Jan 22;25(6):993-9. doi: 10.1016/j.vaccine.2006.09.076. Epub 2006 Oct 10.
10
Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
J Virol Methods. 2007 Jul;143(1):29-37. doi: 10.1016/j.jviromet.2007.02.004. Epub 2007 Mar 19.

引用本文的文献

1
Sub-neutralizing levels of antibodies against RSV F protein enhance RSV infection via Fc-FcγR interactions.
Front Immunol. 2025 Jun 10;16:1594937. doi: 10.3389/fimmu.2025.1594937. eCollection 2025.
2
Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies.
Antibodies (Basel). 2025 Mar 5;14(1):22. doi: 10.3390/antib14010022.
3
Antibody-dependent enhancement of coronaviruses.
Int J Biol Sci. 2025 Feb 3;21(4):1686-1704. doi: 10.7150/ijbs.96112. eCollection 2025.
4
Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement.
Immunol Rev. 2024 Nov;328(1):221-242. doi: 10.1111/imr.13393. Epub 2024 Sep 13.
6
Multifaceted roles of Fcγ receptors in COVID-19 and vaccine responses.
Am J Transl Res. 2023 May 15;15(5):3040-3059. eCollection 2023.
7
Pseudotyped Viruses for Marburgvirus and Ebolavirus.
Adv Exp Med Biol. 2023;1407:105-132. doi: 10.1007/978-981-99-0113-5_6.
8
Antibody-Dependent Enhancement (ADE) and the role of complement system in disease pathogenesis.
Mol Immunol. 2022 Dec;152:172-182. doi: 10.1016/j.molimm.2022.11.010. Epub 2022 Nov 10.
9
Anti- single-chain variable fragments show direct bactericidal activity.
Iran J Basic Med Sci. 2022 Sep;25(9):1141-1149. doi: 10.22038/IJBMS.2022.64062.14106.

本文引用的文献

1
Epitopes involved in antibody-mediated protection from Ebola virus.
Science. 2000 Mar 3;287(5458):1664-6. doi: 10.1126/science.287.5458.1664.
2
DNA immunization: mechanistic studies.
Vaccine. 1999 Mar 26;17(13-14):1612-9. doi: 10.1016/s0264-410x(98)00418-6.
3
Potential advantages of DNA immunization for influenza epidemic and pandemic planning.
Clin Infect Dis. 1999 Feb;28(2):225-9. doi: 10.1086/515123.
4
Immune response to filovirus infections.
Curr Top Microbiol Immunol. 1999;235:205-17. doi: 10.1007/978-3-642-59949-1_11.
5
Experimental filovirus infections.
Curr Top Microbiol Immunol. 1999;235:117-43. doi: 10.1007/978-3-642-59949-1_8.
6
Filovirus diseases.
Curr Top Microbiol Immunol. 1999;235:85-95. doi: 10.1007/978-3-642-59949-1_6.
7
Processing of the Ebola virus glycoprotein.
Curr Top Microbiol Immunol. 1999;235:35-47. doi: 10.1007/978-3-642-59949-1_3.
10
Processing of the Ebola virus glycoprotein by the proprotein convertase furin.
Proc Natl Acad Sci U S A. 1998 May 12;95(10):5762-7. doi: 10.1073/pnas.95.10.5762.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验